I am new to the board, but not the stock. I will not be an active poster. Bottom line, if Ganetespib is approved for just one indication, then this stock is 30+ with ease. Based on my significant due diligence, in my opinion, we have a really good chance. If Ganetespid flops across the board, we are toast. So clearly this is a speculative stock. I am bullish on SYNTA because their Hsp90 inhibitor, Ganetespid, has great safety data, and has shown significant activity in phase 1 and 2 trials. Will this trend play out in phase III studies and result in an approval? Place your bets. If approved for more than one indication, than pick a number over 50.
My concerns with this stock, as in the development of any new drug, is a phase 111 flop, or maybe a long term market melt down, which will take no prisoners. Money in the short term will not be an issue if the data continues positive. The company still talks of one or two deals, and I am sure bankers are clamoring to raise them money.
I do not invest with rose colored glasses. So I respect any bear on this stock if they present well thought out counter arguments based on factual, detailed science against Ganetespid. Nobody on this board cares about somebody's macro view on the market and economy or if we should buy gold or silver. Most of us, including myself and the "pros", are horrible at predicting market movements anyway.
Mark this post: Synta is the new Onyx and will reach a comparable market cap within not so long. Our HSP 90 is not only good, its a slam dunk. Never have I been folowing a drug that as exhibited this good results before in the most stubborn of cancers, namey NSCLC. This will reach 30 when approved and the ph 2 to 3 will glide through approval like nife through butter. Happy weekend from Dr. Ving.